Trial · NCT02839642
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
NCT02839642, Phase 3, Completed, Assistance Publique Hopitaux De Marseille
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy. Trials, record NCT02839642. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02839642
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
- NCT number
- NCT02839642
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 106 participants, actual
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Rivastigmine, Placebo
- First posted
- 2016-07-21
- Last updated
- 2023-07-20
- Other registries' IDs
- eudract:2016-001319-19
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy will be assessed at 4 months as the change from baseline of the number of falls and near falls over the past 2 week | baseline, 2 weeks, 4 months | Efficacy will be assessed at 4 months as the change from baseline of the number of falls and near falls over the past 2 weeks using fall postcards sent weekly and filled daily by the subject and caregiver. The number of falls and near-falls will be expressed both as the total number of occurrences over that period and as the number of occurrence adjusted to the distance and number of hours walked (assessed using continuous accelerometer recordings) |
| Secondary | Change from baseline at 4 months measured by the global ans sub scores of the PSPRS scale (Progressive Supranuclear Palsy Rating Scale) | Baseline and 4 months | |
| Secondary | Change from baseline at 4 months measured by the Clinical Global Impression scale (patient and caregiver) | Baseline and 4 months | |
| Secondary | Apathy assessed using the Lille Apathy Rating Scale (LARS) both subject and caregiver versions | Baseline and 4 months | |
| Secondary | Assessment of the Quality of life of patient using the PSP-Quality of Life Scale (PSP-QoL) | Baseline and 4 months | |
| Secondary | Assessment of the Quality of life of patient using the EQ-5D | Baseline and 4 months | |
| Secondary | Assessment of the Quality of life of the caregiver using the PSP-Quality of Life Scale (PSP-QoL) | Baseline and 4 months | |
| Secondary | Assessment of the Quality of life of the caregiver using the EQ-5D | Baseline and 4 months | |
| Secondary | Caregiver burden assessed using the Caregiver Reaction Assessement (CRA) | Baseline and 4 months | |
| Secondary | Safety: recording of adverse events at each study visit and at the phone calls | 4 months | Vital signs, laboratory tests and ECGs will be performed at each study visit to monitor any biological or cardiac adverse event |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02839642
GET https://conductscience.org/api/trials/v1/NCT02839642/registered